Alejandra Leyton

Ms. Alejandra Leyton

Immunoreceptors of the Innate and Adaptive Systems, Institut d’Investigacions Biomèdiques August Pi i Sunyer
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 December 2020 in Cells
Verified
Journal Article
Open access
PDF file
MAMaría Velasco-De Andrés
María Velasco-De Andrés
SCSergi Casadó-Llombart
Sergi Casadó-Llombart
CCCristina Català
Cristina Català
ALAlejandra Leyton
Alejandra Leyton
LFLozano Francisco
Lozano Francisco
Fernando ArandaFernando Aranda
Fernando Aranda
CD5 and CD6 are closely related signal-transducing class I scavenger receptors mainly expressed on lymphocytes. Both receptors are involved in the modulation of the activation and differentiation cell processes triggered by clonotypic antigen-specific receptors present on T and B cells (TCR and BCR, respectively). To serve such a relevant immunomodulatory function, the extracellular region of CD5 and CD6 interacts with soluble and/or cell-bound endogenous counterreceptors but also microbial-associated molecular patterns (MAMPs). Evidence from genetically-modified mouse models indicates that the absence or blockade of CD5- and CD6-mediated signals results in dysregulated immune responses, which may be deleterious or advantageous in some pathological conditions, such as infection, cancer or autoimmunity. Bench to bedside translation from transgenic data is constrained by ethical concerns which can be overcome by exogenous administration of soluble proteins acting as decoy receptors and leading to transient “functional knockdown”. This review gathers information currently available on the therapeutic efficacy of soluble CD5 and CD6 receptor infusion in different experimental models of disease. The existing proof-of-concept warrants the interest of soluble CD5 and CD6 as safe and efficient immunotherapeutic agents in diverse and relevant pathological conditions.

Verified
Journal Article
Open access
PDF file
SCSergi Casadó-Llombart
Sergi Casadó-Llombart
MAMaría Velasco-De Andrés
María Velasco-De Andrés
CCCristina Català
Cristina Català
ALAlejandra Leyton
Alejandra Leyton
LFLozano Francisco
Lozano Francisco
EBElena Bosch
Elena Bosch
Pathogens are one of the main selective pressures that ancestral humans had to adapt to. Components of the immune response system have been preferential targets of natural selection in response to such pathogen-driven pressure. In turn, there is compelling evidence showing that positively selected immune gene variants conferring increased resistance to past or present infectious agents are today associated with increased risk for autoimmune or inflammatory disorders but decreased risk of cancer, the other side of the same coin. CD5 and CD6 are lymphocytic scavenger receptors at the interphase of the innate and adaptive immune responses since they are involved in both: (i) microbial-associated pattern recognition; and (ii) modulation of intracellular signals mediated by the clonotypic antigen-specific receptor present in T and B cells (TCR and BCR, respectively). Here, we review available information on CD5 and CD6 as targets of natural selection as well as on the role of CD5 and CD6 variation in autoimmunity and cancer.